Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price on Feb 6, 2025
Revance Therapeutics Revenue
Revance Therapeutics had revenue of $59.88M in the quarter ending September 30, 2024, with 10.66% growth. This brings the company's revenue in the last twelve months to $256.95M, up 25.82% year-over-year. In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth.
Revenue (ttm)
$256.95M
Revenue Growth
+25.82%
P/S Ratio
n/a
Revenue / Employee
$430,394
Employees
597
Market Cap
383.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 234.04M | 101.48M | 76.55% |
Dec 31, 2022 | 132.57M | 54.77M | 70.40% |
Dec 31, 2021 | 77.80M | 62.47M | 407.65% |
Dec 31, 2020 | 15.33M | 14.91M | 3,610.65% |
Dec 31, 2019 | 413.00K | -3.32M | -88.92% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRVNC News
- 8 months ago - Rosen Law Firm Urges Revance Therapeutics, Inc. (NASDAQ: RVNC) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
- 8 months ago - RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 - GlobeNewsWire
- 8 months ago - Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC - PRNewsWire
- 8 months ago - Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNC - GlobeNewsWire
- 9 months ago - Crown Laboratories Completes Acquisition of Revance Therapeutics - Business Wire
- 9 months ago - Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics - PRNewsWire
- 9 months ago - Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer - PRNewsWire
- 9 months ago - Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline - PRNewsWire